Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-vegf”

40 pharma patents match "anti-vegf" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 40
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 40 pharmaceutical patents matching "anti-vegf" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

40 results for “anti-vegf” · 30,257 patents in full index Clear search

  1. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  2. WO 2025120867

    POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET ANTICORPS ANTI-VEGFR2

    ASTELLAS PHARMA INC [JP] · Granted Jun 12, 2025 · Expires Jun 7, 2045

    granted
  3. US 12319728

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  4. US 12209120

    Activatable anti-VEGF scFv

    The Regents of the University of California · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  5. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  6. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  7. US 12077570

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  8. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  9. US 12054532

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  10. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  11. US 12012445

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  12. US 12012444

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  13. US 11958894

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  14. US 11938226

    Abiotic anti-VEGF nanoparticle

    The Regents of the University of California · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  15. US 11769597

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted
  16. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  17. US 11732025

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  18. US 11649273

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  19. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  20. US 11542317

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  21. US 11524053

    Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

    The Regents of the University of California · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  22. US 11519020

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  23. US 11505593

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  24. US 11505594

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted